FI3692023T3 - Bentsotiatsoliyhdisteitä ja menetelmiä niiden käyttämiseksi neurodegeneratiivisten häiriöiden hoitoon - Google Patents
Bentsotiatsoliyhdisteitä ja menetelmiä niiden käyttämiseksi neurodegeneratiivisten häiriöiden hoitoon Download PDFInfo
- Publication number
- FI3692023T3 FI3692023T3 FIEP18864678.0T FI18864678T FI3692023T3 FI 3692023 T3 FI3692023 T3 FI 3692023T3 FI 18864678 T FI18864678 T FI 18864678T FI 3692023 T3 FI3692023 T3 FI 3692023T3
- Authority
- FI
- Finland
- Prior art keywords
- yyli
- karboksamidi
- bentso
- fluori
- tiatsol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762566649P | 2017-10-02 | 2017-10-02 | |
| US201862666800P | 2018-05-04 | 2018-05-04 | |
| US201862696432P | 2018-07-11 | 2018-07-11 | |
| PCT/KR2018/011660 WO2019070093A1 (en) | 2017-10-02 | 2018-10-01 | BENZOTHIAZOL COMPOUNDS AND METHODS OF USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3692023T3 true FI3692023T3 (fi) | 2023-08-17 |
Family
ID=65897719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18864678.0T FI3692023T3 (fi) | 2017-10-02 | 2018-10-01 | Bentsotiatsoliyhdisteitä ja menetelmiä niiden käyttämiseksi neurodegeneratiivisten häiriöiden hoitoon |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10669246B2 (https=) |
| EP (1) | EP3692023B1 (https=) |
| JP (2) | JP2020536116A (https=) |
| KR (1) | KR102858188B1 (https=) |
| CN (1) | CN111315727B (https=) |
| AU (1) | AU2018346051B2 (https=) |
| CA (1) | CA3078173A1 (https=) |
| ES (1) | ES2953025T3 (https=) |
| FI (1) | FI3692023T3 (https=) |
| HU (1) | HUE062526T2 (https=) |
| IL (1) | IL273705B2 (https=) |
| MX (1) | MX2020003593A (https=) |
| PL (1) | PL3692023T3 (https=) |
| PT (1) | PT3692023T (https=) |
| WO (1) | WO2019070093A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018346051B2 (en) | 2017-10-02 | 2022-11-10 | 1st Biotherapeutics Inc. | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders |
| AU2020224401A1 (en) | 2019-02-22 | 2021-10-14 | 1ST Biotherapeutics, Inc. | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders |
| EP3934702B1 (en) * | 2019-03-07 | 2024-05-08 | 1st Biotherapeutics, Inc. | [ 18f]-labeled benzothiazole derivative as pet radiotracer |
| US10385046B1 (en) * | 2019-03-19 | 2019-08-20 | 1ST Biotherapeutics, Inc. | Processes for preparing benzothiazol compounds and methods of using the same for treating neurodegenerative disorders |
| KR20210134065A (ko) * | 2019-03-28 | 2021-11-08 | 주식회사 퍼스트바이오테라퓨틱스 | 벤조티아졸 화합물의 약제학적 염, 다형체 및 이들의 제조 방법 |
| CN110483402B (zh) * | 2019-08-12 | 2021-07-23 | 上海毕得医药科技股份有限公司 | 一种3-溴-5-苯基-1h-吡唑的合成方法 |
| CN115968362B (zh) * | 2020-08-21 | 2025-06-13 | 第一生物治疗股份有限公司 | 作为pet放射性示踪剂的[18f]-标记的咪唑并吡啶衍生物 |
| US12398156B2 (en) | 2020-08-21 | 2025-08-26 | 1ST Biotherapeutics, Inc. | Compounds for prevention or treatment of neurodegenerative disorders |
| WO2022064459A1 (en) * | 2020-09-28 | 2022-03-31 | 1ST Biotherapeutics, Inc. | Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same |
| MX2023003698A (es) * | 2020-09-30 | 2023-06-15 | Asahi Kasei Pharma Corp | Compuesto biciclico que contiene nitrogeno y pirimidina. |
| TWI898106B (zh) * | 2022-01-11 | 2025-09-21 | 日商旭化成製藥股份有限公司 | 含有嘧啶之含氮雙環化合物 |
| CN116813608B (zh) * | 2023-06-08 | 2024-03-22 | 英矽智能科技(上海)有限公司 | 噻唑类化合物及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1187453A (en) * | 1915-09-20 | 1916-06-13 | Allis Chalmers Mfg Co | Steam-turbine. |
| US2258671A (en) * | 1940-01-27 | 1941-10-14 | Nat Oil Prod Co | Refining of fat-soluble vitamincontaining materials |
| ATE315394T1 (de) * | 1997-11-10 | 2006-02-15 | Bristol Myers Squibb Co | Benzothiazole als protein tyrosin-kinase inhibitoren |
| KR20020084116A (ko) | 2000-02-07 | 2002-11-04 | 애보트 게엠베하 운트 콤파니 카게 | 2-벤조티아졸릴 우레아 유도체 및 이의 단백질 키나제억제제로서의 용도 |
| CN101384586A (zh) * | 2006-02-14 | 2009-03-11 | 诺华公司 | Pi-3激酶抑制剂及其应用方法 |
| PE20070978A1 (es) * | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
| EP2058309A4 (en) | 2006-08-04 | 2010-12-22 | Takeda Pharmaceutical | CONDENSED HETEROCYCLIC COMPOUND |
| CA2693232A1 (en) | 2007-07-18 | 2009-01-22 | Novartis Ag | Bicyclic heteroaryl compounds and their use as kinase inhibitors |
| TW200911798A (en) | 2007-08-02 | 2009-03-16 | Amgen Inc | PI3 kinase modulators and methods of use |
| US8993580B2 (en) * | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| AR071523A1 (es) | 2008-04-30 | 2010-06-23 | Merck Serono Sa | Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento |
| WO2010008847A2 (en) | 2008-06-24 | 2010-01-21 | Takeda Pharmaceutical Company Limited | Pi3k/m tor inhibitors |
| BRPI0915231A2 (pt) * | 2008-07-08 | 2018-06-12 | Intellikine Inc | compostos inibidores de quinase e métodos de uso |
| JP4528849B2 (ja) * | 2008-07-14 | 2010-08-25 | シャープ株式会社 | 引出し型加熱調理器 |
| WO2010100144A1 (en) | 2009-03-04 | 2010-09-10 | Merck Serono S.A. | Fused bicyclic compounds as inhibitors for pi3 kinase |
| US8765747B2 (en) | 2009-06-12 | 2014-07-01 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
| EA026115B1 (ru) * | 2010-12-17 | 2017-03-31 | Ф. Хоффманн-Ля Рош Аг | Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение |
| KR20140107153A (ko) * | 2014-07-23 | 2014-09-04 | 한국과학기술원 | 인돌 유도체 화합물, 이를 포함하는 Ａｂｌ 키나제 저해제 조성물 및 이상세포 성장 질환의 예방 및 치료용 약학 조성물 |
| AU2018346051B2 (en) | 2017-10-02 | 2022-11-10 | 1st Biotherapeutics Inc. | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders |
-
2018
- 2018-10-01 AU AU2018346051A patent/AU2018346051B2/en active Active
- 2018-10-01 ES ES18864678T patent/ES2953025T3/es active Active
- 2018-10-01 PT PT188646780T patent/PT3692023T/pt unknown
- 2018-10-01 US US16/148,265 patent/US10669246B2/en active Active
- 2018-10-01 WO PCT/KR2018/011660 patent/WO2019070093A1/en not_active Ceased
- 2018-10-01 JP JP2020520037A patent/JP2020536116A/ja active Pending
- 2018-10-01 FI FIEP18864678.0T patent/FI3692023T3/fi active
- 2018-10-01 KR KR1020207012653A patent/KR102858188B1/ko active Active
- 2018-10-01 CN CN201880063869.7A patent/CN111315727B/zh active Active
- 2018-10-01 PL PL18864678.0T patent/PL3692023T3/pl unknown
- 2018-10-01 EP EP18864678.0A patent/EP3692023B1/en active Active
- 2018-10-01 HU HUE18864678A patent/HUE062526T2/hu unknown
- 2018-10-01 MX MX2020003593A patent/MX2020003593A/es unknown
- 2018-10-01 CA CA3078173A patent/CA3078173A1/en active Pending
-
2020
- 2020-03-30 IL IL273705A patent/IL273705B2/en unknown
- 2020-05-14 US US15/931,827 patent/US10968188B2/en active Active
-
2023
- 2023-05-15 JP JP2023080175A patent/JP7605898B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020112784A3 (https=) | 2022-03-05 |
| AU2018346051B2 (en) | 2022-11-10 |
| MX2020003593A (es) | 2020-07-22 |
| JP2023109868A (ja) | 2023-08-08 |
| JP2020536116A (ja) | 2020-12-10 |
| KR20200051832A (ko) | 2020-05-13 |
| RU2020112784A (ru) | 2021-11-09 |
| IL273705B2 (en) | 2023-02-01 |
| US20200270222A1 (en) | 2020-08-27 |
| PT3692023T (pt) | 2023-08-23 |
| EP3692023B1 (en) | 2023-05-17 |
| CN111315727B (zh) | 2023-09-29 |
| JP7605898B2 (ja) | 2024-12-24 |
| IL273705B (en) | 2022-10-01 |
| IL273705A (en) | 2020-05-31 |
| US10669246B2 (en) | 2020-06-02 |
| WO2019070093A1 (en) | 2019-04-11 |
| PL3692023T3 (pl) | 2023-12-11 |
| ES2953025T3 (es) | 2023-11-07 |
| CA3078173A1 (en) | 2019-04-11 |
| EP3692023A1 (en) | 2020-08-12 |
| US20190100500A1 (en) | 2019-04-04 |
| CN111315727A (zh) | 2020-06-19 |
| HUE062526T2 (hu) | 2023-11-28 |
| US10968188B2 (en) | 2021-04-06 |
| KR102858188B1 (ko) | 2025-09-11 |
| EP3692023A4 (en) | 2021-04-07 |
| AU2018346051A1 (en) | 2020-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3692023T3 (fi) | Bentsotiatsoliyhdisteitä ja menetelmiä niiden käyttämiseksi neurodegeneratiivisten häiriöiden hoitoon | |
| IL288236A (en) | 3,2-dihydroquinazoline compounds as inhibitors of nav1.8 | |
| MX379169B (es) | Amidas heterocíclicas útiles como moduladores de proteínas. | |
| WO2018042343A3 (en) | Compounds that inhibit 3c and 3cl proteases and methods of use thereof | |
| WO2018006074A3 (en) | Compounds and methods for modulating rna function | |
| EP3495391A4 (en) | ANTIBODIES AGAINST PROGRAMMED DEATH LIGAND 1 (PD-L1) AND USE OF IT | |
| EP3317282A4 (en) | Substituted 4-methyl-pyrrolo[1.2-a]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity | |
| WO2018023072A3 (en) | Compounds and compositions and uses thereof | |
| EP3860571A4 (en) | Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide | |
| EP3952877A4 (en) | HETEROCYCLIC COMPOUNDS AND THEIR USES | |
| WO2018101663A3 (ko) | 생체 조직 투명화용 조성물 및 이를 이용한 생체 조직 투명화 방법 | |
| WO2017156495A8 (en) | Compounds and methods for modulating bruton's tyrosine kinase | |
| MX360703B (es) | Proceso mejorado para la elaboración de 5-(2, 6-di-4-morfolinil-4-pirimidinil)-4-trifluoro-metil-piridin-2-amin a. | |
| EP4339192A3 (en) | Compounds and compositions for the treatment of cancer | |
| IL284765A (en) | 8,1-naphthyridinone compounds and their uses | |
| WO2020127259A3 (en) | Materials for electronic devices | |
| SG11201901773QA (en) | Nitrogenous heterocyclic aromatic compound, preparation method therefor, pharmaceutical composition thereof, and application thereof | |
| EP3863631A4 (en) | PYRIMIDINE AND PYRAZINE HDAC 1, 2 INHIBITORS | |
| PL3430113T3 (pl) | Sposób kontrolowania nieprzyjemnego zapachu „potu” z zastosowaniem przetrwalników bakterii zdolnych do hamowania lub zapobiegania tworzeniu się takiego nieprzyjemnego zapachu | |
| WO2018211323A8 (en) | Heterocyclic compounds for the treatment of disease | |
| WO2018211324A8 (en) | Prodrugs for the treatment of disease | |
| EP3541801A4 (en) | 4- (6- (2- (2,4-DIFLUORPHENYL) -1,1-DIFLUOR-2-HYDROXY-3- (5-MERCAPTO-1H | |
| WO2018146390A8 (fr) | Utilisation d'un compose appartenant a la famille des diuretiques pour traiter le cancer | |
| EP3759079A4 (en) | AMYLOID PROTEIN SELECTIVE BACE INHIBITORS (ASBIS) FOR ALZHEIMER'S DISEASE | |
| EP3699287A4 (en) | 1,5-DIAMINOPENTANE PURIFICATION PROCESS |